An Open-label Study to Evaluate the Pharmacokinetics (PK) of Darunavir (DRV) and Cobicistat (COBI) After a Single-oral Administration of Darunavir/Cobicistat Fixed-Dose Combination Tablet in Healthy Japanese Adult Subjects
Phase of Trial: Phase IV
Latest Information Update: 14 Jun 2018
Price : $35 *
At a glance
- Drugs Cobicistat/darunavir (Primary)
- Indications HIV-1 infections
- Focus Pharmacokinetics
- Sponsors Janssen Pharmaceutical KK
- 26 May 2017 Status changed from recruiting to completed.
- 24 Apr 2017 New trial record
- 21 Apr 2017 Status has been changed from not yet recruiting to recruiting.